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Abstract 
The purpose of this study was to investigate the cortisol levels as function of hypothalamic-
pituitary-adrenal axis (HPA) in relation to alexithymia in patients with Somatoform disorders 
(SFD). 32 patients with somatoform disorder sampled diurnal salivary cortisol, had a 
psychiatric investigation and filled in questionnaires (TAS-scale; SOMS-scale; HAM-D). 
Mean TAS-score in the sample was elevated (55.6 ± 9.6), relative to the German Normative 
sample. 32% of patients were classified as alexithymic based on their TAS scores. 
Depression scores were moderate (HAM-D 13.2, BDI 16.5). Patients’ alexithymia scores 
(TAS scale “Difficulty identifying feelings”) were significantly positively correlated with their 
Somatization-scale scores (SCL-90-R); r=0.3438 p<0.05) and their scores on the GSI on 
SCL-90-R; r=0.781 p<0.01).  Regression analysis with cortisol variables as dependent 
variables was performed. Cortisol levels (measured by AUC-G, AUC-I and MCS) were best 
predicted in a multiple linear regression model by lower depressive scores (HAM-D), more 
symptoms of psychopathology (SCL-90-R)> Cortisol levels were positively correlated to the 
patients’ scores on the “Somatization severity scale” of SOMS-scale, but negatively 
correlated to the patients’ scores on the Somatization scale (SCL-90-R). No significant 
correlations were found between the patients’ Alexithmyia-scores (TAS) and cortisol levels. 
The control-group demonstrated significantly higher levels of cortisol than did the patients 
with SFD; both tests; p<0.001 for AUC (G) and AUC (I). However, the two groups did not 
differ in terms of their mean morning cortisol levels  (p >0.05) 
Author-Supplied Keywords:  
Somotaform Disorders – Cortisol – Alexithymia  
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Abbreviation: TAS = Toronto-Alexithymia-Scale; HAM-D = Hamilton-Depression scale; 
SCL-90-R = Symptom Checklist-90 Revised; GSI =global severity index; SOMS = Screening 
for Somatoform Symptoms; Somatoform Disorders = SFD; AUC-G = Area under the curve-
ground; AUC-I = Area under the curve- increase; MCS =Morning cortisol.  
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1. Introduction 
Somatoform disorders (SFD) are characterized by bodily symptoms that cannot be 
explained by organic pathology or known physiological mechanisms. Previous studies (e.g. 
Bach & Bach, 1995; Bankier et al. 2001; Pedrosa Gil et al., 2006) have reported that patients 
with SFD exhibit elevated levels of alexithymia. Alexithymia is a concept that was developed 
by Sifneos (1973) and means literally “absence of words for emotion”. Alexithymia is 
characterised by an inability to describe and identify feelings, by an absence of fantasies, 
and a tendency to utilise an externally focused analytical cognitive style. The concept of 
alexithymia has been examined in a variety of different medical and psychiatric disorders 
(Sifneos, 2000; Naatanen et al, 1999; Pedrosa Gil et al, 2006; Wise et al., 2000). Empirical 
findings support the conceptualisation of alexithymia (i.e. “absence of words for emotion”) 
and the clinical impression of an association between somatization and alexithymia (Bankier 
et al., 2001, Bach et al., 1995, De Gucht et al., 2003).  
 
The stress-alexithymia-hypothesis (Martin et al., 1986) proposes that the inability of 
alexithymic individuals to identify and express emotion prevents them from coping effectively 
with stressful events and results in prolonged and elevated autonomic activity. The ensuing 
chronic activation of the hypothalamic-pituitary-adrenal (HPA) axis is associated with 
elevated levels of circulating adrenal hormones, most notably cortisol, which in turn lead to 
stress-related medical and behavioural problems.  It has been suggested (e.g. Papciaks et 
al., 1985;  Stone & Nielson, 2001) that when individuals with alexithymia encounter a 
negative stimulus or event they experience a decoupling of subjective and physiological 
arousal and that this decoupling increases the risk of developing stress related illness. In line 
with these suggestions, empirical studies have provided evidence of elevated sympathetic 
activation, indexed by tonic heart rate (Wehmer et al., 1995) and electrodermal activity 
(Friedlander et al., 1997), in participants with elevated levels of alexithymia.  However, these 
measures only provide an index of general arousal. In order to directly investigate changes 
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in the activity of HPA axis it is appropriate to measure the levels of the adrenal hormones, 
most notably cortisol, that are circulating in the blood. Importantly, previous studies have 
reported that salivary cortisol concentrations can also be used as an accurate index of 
activity of the HPA axis (e.g. Melamed et al., 1999, Vedhara et al., 2003). Furthermore, 
salivary cortisol has been shown to be a reliable marker of stress that is comparable to 
plasma cortisol (Weibel, 2003). An advantage of using saliva samples as opposed to blood 
samples is that they can be collected in a non-stressful manner (Kirschbaum and 
Hellhammer, 1994). 
 
Rief et al. (1998) examined HPA-axis activity in patients with SFD and found higher 
morning cortisol levels in patients compared to normal controls. However in a second study 
(Rief et al., 2000), which also included a dexamethasone suppression test (DST), this finding 
was not be replicated. In another study (Heim et al., 1998) results indicated that female 
patients with functional chronic pelvic pain exhibited hypofunctional HPA axis, indexed by 
elevated cortisol. However, it should be noted that these patients did not exhibit any 
depressive symptoms. This is important as elevated cortisol levels have been consistently 
reported in patients with depression (e.g. Bhagwagar et al, 2005; O’Brien et Al, 2004). Ehlert 
et al. (2005) examined HPA axis activity in patients with functional gastrointestinal disorders 
(FGD) and reported two different types of alteration in cortisol levels. Patients with the 
highest pain ratings were found to exhibit low cortisol levels; whereas patients exhibiting the 
highest depression scores were shown to have the highest cortisol levels. These findings 
suggest different psychobiological subgroups for FGD patients; this may also be true of SFD 
patients. One variable that might account for the contradictory and conflicting findings 
concerning the relationship between SFD and HPA activity is alexithymia. It is plausible that 
differences in alexithymia might be related to changes in cortisol levels.   
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The primary purpose of the present study was to investigate associations between 
alexithymia, somatization and salivary cortisol as stress-parameter. Based on the above 
mentioned research strategy, our hypotheses are: (1) There will be a significant positive 
correlation between the participants’ alexithymia scores and the somatization degree, 
indexed by scores on the SCL-90-R scale “somatization” and the “Somatization severity 
scale” on SOMS-scale; (2) There will be a significant positive correlation between HPA 
activation and alexithymia, such that higher cortisol levels will be related to elevated 
alexithymia scores in patients with SFD, in agreement to “stress-alexithymia hypothesis”. 
 
 
2. Methods 
2.1. Participants 
Thirty-two patients (23 female, 9 men) meeting ICD-10 criteria for SFD and twenty-five 
healthy controls (19 female, 6 men) took part in the present study. The characteristics of the 
participants in the two groups are presented in Table 1. For age (p=0.11) and sex (p=0.771) 
there are no statistically significant differences between patient group with SFD and healthy 
subjects. 34 patients with SFD provided salivary cortisol samples. Two patients were 
excluded from analysis because of unusually high cortisol levels (> 1.5 interquartile lengths 
below /  above the 25. / 75. percentile) on more than two sampling points. Two other patients 
who did not fill in the SCL-90-R were included in analysis. 
 
The patients with SFD, who were recruited from the Psychosomatic Ambulance of 
the Department at the University of Munich, were outpatients who had been referred from 
private practice, or from the Department of Internal Medicine, for diagnostic interview and 
counselling in psychiatric and psychosomatic field. Inclusion criteria for the patient group of 
the present study were the presence of SFD diagnosed according to ICD-10 (n=15 with the 
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diagnosis F 45.0; n=14 with F45.1 and n=3 F 45.3). The diagnosis was established through 
a clinical interview conducted by a trained psychiatrist (P.G.F.), who performed extensive 
physical and psychological assessment of the patients (after somatic disorders had been 
excluded during extensive inpatient or outpatient investigation at the medical clinic or in 
general practice); including checking for the signs and symptoms of somatoform disorders 
as outlined in the diagnostic criteria cited in the ICD-10 (Hiller et al., 1996). A further aid to 
the diagnosis of SFD was that the participants’ fulfil the criteria on the SOMS questionnaire 
(Rief et al., 1997).  Exclusion criteria were presence of major medical disorders (e.g. 
autoimmune-, neoplasms, cardiac-, pulmonary-, or endocrine diseases), psychosis, 
substance abuse disorders, major affective disorders, co-medication with benzodiazepine or 
other psychotropic medication, as well as steroid-hormone intake respectively contraceptive 
medication during the past four weeks. The patients and health subjects were thus in 
principle drug free in order to minimize pharmacological influence if possible.  It should be 
noted that there was a very high level of psychiatric comorbidity in the patient sample, as 
thirty-two patients exhibited significant symptoms of other psychiatric disorders: 84% (n = 
27) of the patients were affected by psychiatric comorbidity, in first line dysthymia F34.1 (n = 
11) and depressive reaction F43.2 (n = 16). Further additional diagnoses were recurrent 
depressive disorder F 33.0 (n = 3) and eating-disorder (bulimia and others, n = 3). The 
participants (n=25) in the control group were recruited mainly from the community and from 
the student population of medical and nursing schools. In comparison to patients with SFD a 
detailed psychological measurement was not assessed. In general they were in good 
general health and the presence of a serious medical disease (like autoimmune-, 
neoplasms, cardiac-, pulmonary-, or endocrine diseases) or a psychiatric disorder were not 
known. 
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2.2 Study protocol, procedure 
If patients fulfilled inclusion criteria they were asked to participate in the study. During 
their study visit, patients filled in some of the questionnaires. Patients were instructed to 
collect saliva samples during the next two days. The study protocol was approved by the 
Ethical Committee of the University Munich in accordance with the declaration of Helsinki. 
Written informed consent was obtained from each patient before study inclusion. 
 
2.3. Questionnaires and measures 
The SOMS (Rief et al., 1997) is a self-rating questionnaire checking for 53 physical 
symptoms. The questionnaire includes all 33 physical complaints of the DSM-IV 
somatization disorder symptom list, the symptoms of ICD-10 somatization disorder, and the 
ICD-10 somatoform autonomic dysfunction symptom list. This questionnaire requires the 
participants to report if they had experienced any or all of 53 physical symptoms during the 
past 2 years. They were instructed only to answer "yes" if the symptoms had a significant 
influence on their subjective well being and if doctors did not find a sufficient explanation for 
the complaints. Thus, persons with physical illness were not excluded but were instructed 
only to report physically unexplained symptoms. Item 54 to item 68 of the SOMS cover all 
inclusion and exclusion criteria (first complaints before age 30 years, symptom duration, 
acceptance of doctor’s explanation that the complaints do not have a physical origin, doctor 
visits due to the symptoms, etc.). Adding the number of positively answered symptoms 
allows computation of the "somatization index" (range from 0 to 33 points), used also in our 
study. The number of somatization symptoms correlated r = 0.75 between self-ratings and 
interview, confirming the high validity of the SOMS. 
 
The 90-item version of the Symptom Checklist-90 Revised (Derogatis, 1994) reveals 
different aspects of psychopathology, it assesses patients’ current symptoms within a 
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specified and optimal point-in-time (i.e., the past 7 days). The SCL-90-R includes three 
global index scales and nine symptom scales that were based on factor analysis and that 
include diagnostic-specific and non-specific symptoms. Patients are instructed to rate mental 
health symptoms that have “bothered” them within the past 7 days on a 5-point scale (0–4) 
ranging from “Not at All” (i.e., a “0” rating) to “Extremely” (i.e., a “4” rating). The symptom 
scales include the Somatization, Obsessive-Compulsive, Interpersonal Sensitivity, 
Depression, Anxiety, Hostility, Phobic Anxiety, Paranoid Ideation, and Psychoticism scales. 
The SCL-90-R index scales include the Positive Symptom Total, Positive Symptom Distress 
Index, and Global Severity Index. SCL-90-R index and symptom scale scores are 
represented as T-scores, with a mean of 50 and a standard deviation of 10. Higher T-scores 
reflect greater number and/or severity of patient self-reported symptoms. We defined a 
“clinically significant” or “elevated” scale score to be a T-score of 63 or higher, based on 
recommendations (Derogatis, 1994). 
The German version of the 26-item Toronto Alexithymia Scale (TAS-26; Kupfer et al., 
2000, 2001) was used in the present study to assess the presence and severity of 
alexithymia in the participants.  This measure includes 26 items that generate scores on 
three dimensions: “difficulty identifying feelings”; “difficulty describing feelings” and 
“externally orientated thinking”. This three-factor structure has been replicated in clinical and 
non-clinical groups. The German version of the TAS-26 was validated with a representative 
population sample (n=2084) and shows reasonable internal consistency ranging between 
r=.67 and r=.84. The overall TAS-26 scores range from 18 to 90. The cut-off point, which 
differentiates between alexithymic and non-alexithymic individuals, is > 54. 
The Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960) was included in 
the present study to provide an observer-rated measure of depression severity. This 
assessment was conducted by a fully trained psychiatrist (P.G.F). The 21-item Beck-
Depression-Inventory (BDI; Beck et al., 1961) was utilised in the present study to provide an 
index of self-rated depression severity.  
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2.4. Saliva cortisol sampling and biochemical analysis 
Saliva samples were collected using a small cotton swab with no additives 
(Salivette®, Sarstedt, Numbrecht, Germany). Participants were instructed to chew on the 
swab for 3 minutes, put the swab into the Salivette, note the time of sampling, keep the 
samples at ambient temperature and return them to the lab within 1 week. Samples were 
collected from each subject on two days (at both days at 8 a.m. and at 12 p.m., 4 p.m., 8 
p.m.) in order to get a circadian profile of cortisol secretion. All saliva samples were stored in 
the laboratory at - 20°C until analysis. Cortisol concentrations were determined employing a 
highly sensitive chemiluminescence immunoassay (Cortisol Saliva LIA, IBL, Hamburg, 
Germany). Endpoint detection was done using a chemiluminescence reader (Victor, Perkin 
Elmer, Rodgau, Germany). The assay shows a relevant cross reaction with the following 
steroids: Prednisolone (57%), 11-deoxycortisol (12%), corticosterone (2.5%), cortisone (2%) 
and prednisolone (1%). Patients on steroid treatment were excluded from the study. The 
lower detection limit of this assay is less than 0.16 ng/ml. To reduce error variance caused 
by interassay imprecision, all samples from one subject were assayed in the same run. In 
our study, within-assay CV was 7.2% and 5.4% at 0.8 and 5.0 ng/ml, respectively. Between-
assay CV at the same concentrations was 9.45 and 6.6%, respectively.  
 
2.5. Cortisol data analysis 
The area under the curve (AUC), which integrates data from the single 
measurements, was calculated according to two formulas proposed by Pruessner et al. 
(2003). Eight equidistant measured values from day 1 and day 2 were used. The formulas 
are derived from the trapezoid formula and contain different forms of information. AUCg 
(ground) contains more information on cortisol levels, whereas AUCi refers to the increase or 
decrease over time and therefore provides information on the sensitivity of the system. AUC 
s were calculated by the following formulae (2) and (3),  
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with m as the individual measurement (1 to 8 in this case) and n as the total number of 
measurements (8). As an usual measure of variability, the coefficient of variation was 
computed by:  
100*
m
sdCV  %           (4), 
with m = mean (m1, m2, ..., m8), and sd = standard deviation (m1, m2, ..., m8). 
 
The morning cortisol level (=MCS) is the average of eight o'clock cortisol level on the two 
measured days. 
 
2.6. Data reduction and statistical analysis 
All data were analysed using SPSS for Windows© 11.5. The data were examined for 
normal distribution using the Shapiro-Wilk Test. According to the scale niveau, Chi²- or T-test 
was used. Correlations between two parameters were analysed using Pearson coefficient.  
To assess whether there are differences between the controls and the participants of the 
study on the variable cortisol, the t-test for independent samples was performed. Multiple 
linear regression analyses using a backwards stepwise algorithm was calculated with 
cortisol measures as dependent variables, age, psychopathology parameters and 
alexithymia as independent variables. The significance level was set to alpha < .05 for each 
statistical test. 
 12
For the univariate statistic evaluations like the correlations in pairs, only 30 persons enter 
analysis for the SCL 90 Since for the SCL 90 in two cases no data are present, altogether 
only 30 persons enter this analysis. With the further parameters all 32 cases entered 
evaluation. With the use of multivariate procedures only the cases are received, for 
regarding all parameters information full in the model, all data are thus present into a model 
(Listwise).  
 
3. Results 
3.1. Participant characteristics and psychopathology 
Specifically, 23 of the SFD patients were female (mean age= 45.0 years, SD=8.1) 
and 9 were male (mean age=42.2 years, SD=8.6) compared to the controls where 19 of the 
sample were female (mean age= 36.3 years, SD=12.7) and 6 were male (mean age= 41.6 
Years, SD=16.1). Analysis of the participant characteristics revealed that the two groups did 
not differ significantly in terms of their age (mean age SFD patients = 44.2 years, Standard 
deviation=8.2; mean age HC = 37.4 years, SD=13.3); p>0.05 p=0.11. Furthermore, the two 
groups did not differ significantly in terms of the ratio of males and females making up each 
group, p>0.05.  Inspection of the participants’ educational background (presented in Table 1) 
revealed that 60% of the SFD patients had completed high school equivalent or higher 
education (with about 28% of the males and 72% of the females achieving this level of 
education). The mean SOMS score of 21.4 ± 8.3 indicates moderate to severe level of 
somatization (Rief et al. 1997). 14 (43.8%) patients had low depression observer ratings 
(HAM-D< 13), 18 (56.3%) patients showed elevated Hamilton scores (data are not shown in 
table).(HAM-D= or >14) Subjective general psychiatric symptomatology as indicated by the 
SCL GSI-score (Global severity index) was significantly elevated (mean T = 64.2 ± 13.6), 
Phobic anxiety in the SFD patients was also moderately elevated (mean = 58.9, SD=11.5). 
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3.2. Assessment of Alexithymia 
Inspection of the data in Table 1 revealed that the patients showed an elevated TAS 
total score (Mean = 55.6, SD= 9.6), with 32% of the patients reaching raw values higher than 
54 (raw value) as cut off value, respectively T-score 61, which are considered to represent 
clinically significant alexithymia (Taylor et al., 1997). Patients demonstrated significantly 
elevated scores on the “Difficulty identifying feelings” sub-score (mean= 60.6, SD= 8.8), 
statistical test result?; whereas patients scores on the “Difficulty describing feelings” and 
“Difficulty externally orientated thinking” sub-scales  lie nearly within the range of normal 
values (Mean= 54.6, SD=11.3 and Mean= 45.38, SD= 9.0 respectively .  
 
3.3. Alexithymia and Psychopathology 
Patients with higher alexithymia scores reported more frequent symptoms in the 
SCL-90-R., for more details see Table 2. TAS factor 1 scores (“Difficulty identifying feelings”) 
were positively correlated with SCL-Somatization-scale (r(n=30?) = .343, p=0.05), but also 
with other scales (2-9, including the GSI). TAS factor 2 (“Difficulty describing feelings”), was 
positively correlated with GSI-scale (r = .39, p-value? n=?). TAS factor 3 scores (“Externally-
oriented thinking”), were negatively correlated with GSI scores (r(n=30) = -.0.37, p-value?). 
Obviously TAS factor 1 (“Difficulty identifying feelings”) is most sensitive to psychopathology 
in comparison to SCL-90R-scales. The “Somatization-severity-score” shows no significant 
correlations to the TAS scores.    
3.4. Analyses of Cortisol 
Mean morning cortisol level of the patients with SFD, averaged for day 1 and day 2, 
was 5.2 ± 3.2 ng/ml, salivary cortisol showed the well-known diurnal decline from morning to 
afternoon, more details see Table 3. AUC ground [=AUC (G)], as a measure for cortisol level 
over time was 7.7 ± 3.4 ng/ml; with an AUC increase [AUC (I)] value of – 8.3 ± 7.7 ng/ml. 
The variation coefficient is 90.0 % ± 25.0 with a decrease of values during the day. Mean 
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morning cortisol level of the healthy controls, averaged for day 1 and day 2, was 6.7 ± 3.9 
ng/ml, salivary cortisol showed for AUC (G) MW = 21,4 and SD = 10,3; and for AUC (I) MW 
= -29,7 and SD = 24,8., see Table 3. The control-group demonstrated significantly higher 
cortisol values for AUC (G) and AUC (I) than did patients with SFD (t-test; p<0.001). The 
mean morning cortisol levels showed no significant difference (t-test; t-value=?, df=?, p 
>0.05) 
 
3.5. Relationship between Cortisol, Alexithymia and Somatization 
The question arises, if cortisol levels depended on the psychopathology, e.g. 
depression and other psychiatric symptoms (measured on SCL-90-R-scale), in addition, on 
the alexithymia scores. In attempt to predict the multiple linear regression analyses were 
conducted with AUC G, AUC I und MCS measures of Cortisol as dependent variables and 
with age, psychopathology parameters (among others GSI of SCL-90-R) and alexithymia as 
the predictor variables (measured in TAS-scales), more details see Table 4. 
Backwards stepwise regression of data from 30 patients who had complete data indicated 
that variance of cortisol ground level AUC G was best explained by HAM-Depression-score 
with negative correlation to AUC-G (-0.44), the global severity index (GSI) of SCL-90-R 
correlated positively with AUC-G (0.72), the Somatization scale (SCL-90-R) correlated 
negatively with AUC-G (-0.47), and the Somatization severity scale correlated positively with 
0.72 to AUC-G. 
This model reached sufficiently high variance prediction (Adjusted R² = .34 (F (30) = 6.2; p = 
.002). Mean morning cortisol (MCS) could not be sufficiently explained by our variables in a 
linear regression model. For AUC I likewise, no significant model could be formulated; all 
variables (except the constant) were excluded. Included and excluded variables and their 
regression coefficients are shown in Table 3. . 
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4. Discussion 
In the present study we examined the levels of salivary cortisol in a sample of 
untreated patients with SFD and a group of healthy controls. We also examined the 
presence of alexithymia in these individuals and tried to establish if there was a relationship 
between the degree of participant alexithymia and their levels of cortisol. As expected there 
was a high prevalence of alexithymia features in patients with SFD and a significant positive 
correlation between alexithymia and somatization as well as more symptoms of 
psychopathology, measured in SCL-90-R. 
Second, contrary to expectations, we found lower cortisol levels in patients with SFD 
in comparison to healthy subjects. This suggests that SFD is associated with hypofunction of 
the HPA axis. Against our predictions, no significant correlation was observed between 
alexithymia scores and cortisol levels. However, observer ratings of depression severity 
(HAM-D scores) were negatively correlated with cortisol levels. Symptom scores  of 
psychopathology (SCL-90-R) and scores on the “Somatization severity scale” of SOMS-
scale were positively correlated with cortisol levels. Conversely, cortisol levels were 
negatively correlated with the patients’ scores on the Somatization scale (SCL-90-R). 
 
In line with our first hypothesis, we found a high prevalence of alexithymia in our 
patients with SFD, 32% reaching clinically significant alexithymia, clearly higher values in 
comparison to non-clinical populations, Kokkonen et al. 2001 (9,4% in male and 5,2% 
alexithymia-values in female subjects), and Posse et al. (2002) found an prevalence of 7,9% 
in a non-clinical female population. The correlation of alexiythmia with somatization in our 
sample is in agreement with prior studies (De Gucht et al., 2003; Lipsanen et al., 2004, 
Waller et al., 2004). Our findings are not consistent with a recent study (Karvonen et al., 
2005) that demonstrated a lower prevalence of alexithymia with only 6.0% among patients 
with somatization and 4.8% among subjects without somatization symptoms.  
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Our data affirmed the hypothesis of Bagby and Taylor (1997) that impaired emotion-
processing capacities that underly alexithymia can lead to a misinterpretation of the somatic 
sensations that accompany emotional arousal, leading to hypochondria and somatization. 
Contrary to second hypothesis, our patients with SFD exhibited reduced cortisol 
levels in comparison to healthy subjects, suggesting the SFD are associated with a 
hypofunction of HPA axis. Additionally, also contrary to our predictions, there were no 
correlations between alexithymia-values and cortisol levels. This does not correspond with 
the decoupling-hypothesis of Stone and Nielson (2001). In addition, the present findings are 
inconsistent with other studies (Wehmer et al., 1995) that have reported that alexithymia 
tends to be associated with tonic physiological hyperarousal. Only a few studies have 
investigated the cortisol response in patients with alexithymia and they have tended to report 
especially low basal cortisol levels (Conrad et al., 2002, Henry et al., 1997).  This tendency 
is confirmed by our results. 
In the last decade some authors (Chrousos and Gold, 1992; Alfvén et al., 1994) 
discussed a hypocortisolism as biological marker of stress-related disorders like chronic 
fatigue syndrome or other idiopathic syndromes. A possible explanation is that –like in 
patients with Addison´s disease with symptoms of fatigue and malaise- a subtle adrenal 
insufficiency is associated with involvement of HPA-axis disturbances e.g. in idiopathic 
syndromes (Ehlert et al., 2001). Heim et al. (2000) summarize in a review that 
hypocortisolism does not merely represent a specific correlate of PTSD, since similar 
findings have been reported for healthy individuals living under conditions of chronic stress 
as well as for patients with several bodily disorders, like chronic fatigue syndrome, 
fibromyalgia, other SFD. Their hypothesis is that a persistent lack of cortisol availability in 
traumatized or chronically stressed individuals may promote an increased vulnerability for 
the development of stress-related bodily disorders. 
. In the current investigation, depression scores, although moderate, were correlated 
weakly with somatization. Comorbidity between symptoms of somatization and depression is 
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well known (Taylor et al., 2004). Rief et al. (1998) confirm a close association between 
depression and SFD by finding high comorbidity rates between them and SFD have been 
labelled as “masked depression” (Kielholz, 1973). Basic and clinical research suggests that 
the pathogenesis of affective disorders, especially depression, is causally related to 
alterations and activation of the hypothalamic-pituitary-adrenal-axis (HPA): The overactivity 
of the HPA-system is reflected by enhanced peripheral levels of cortisol and corticotrophin 
(Holsboer, 2000). But in our investigation at least higher Hamilton depression score 
correlated with lower cortisol levels, but interestingly not the BDI as self-evaluation scale of 
depression, so that we should be careful with the interpretation of our data. These conflicting 
data in our sample could be possibly explained by counteracting effects of psychopathology 
(especially depression) and somatization, e.g. in it reflects that the somatization in 
comparison to depressive comorbidity outweighs on the activity HPA axis. However one 
must consider that no major depressive disorder was present. It is still a matter of 
controversial debate if depression and alexithymia are distinct or overlapping constructs 
(Hintikka et al., 2001).  
 
In the present study we reported that alexithymia was strongly correlated with 
psychopathology. These results are consistent with other other studies (Grabbe et al., 2004) 
and support the hypothesis that the “difficulties identifying feelings” feature of alexithymia is 
highly predictive of a broad range of "state" levels of psychopathology, particularly 
somatization. And in contrast, “difficulties expressing feelings” and “externally orientated 
thinking” were almost not predictive for any of the SCL-90-R scores. In a recent study, Lin et 
al. (2005) reported a negative correlation between TAS factor 3 and changes in the cortisol 
response. Our findings are not consistent with this study. 
At least is to explain the contradictory behaviour of measures of Somatization: The 
Somatization scale (SCL-90-R) correlated negatively with cortisol levels, in contrary the 
Somatization severity scale (SOMS scale) correlated positively. Of importance it is that the 
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Global severity index (GSI) of SCL-90-R correlated too with higher cortisol levels, similar to 
the Somatization severity scale, which also at the other data is comprehensible. In line of the 
stress-alexithymia-hypothesis (Stone and Nielson, 2001) more psychopathology symptoms 
were to be also expected. A similar contradictory result related to the psychology 
measurements so far also in this form one did not report. 
  
Despite the current findings there are a number of issues to be considered. First of 
all, in our healthy control group only cortisol was measured, we have no measures of 
psychopathology. On the other hand our sample of patients and healthy subjects are free of 
major psychiatric disorders and drug free. Secondly, there are some difficulty comparing 
findings across the studies because different instruments were used. The data generated in 
the current investigation was mostly normally distributed and therefore correlation analysis 
within the patients sample generates valuable information. Physiological fluctuations as well 
as the circadian rhythm of cortisol secretion must be taken into account, and differences in 
sampling time points or frequency might explain contradictory results in different studies. To 
get a representative picture of cortisol secretion profiles of 4 samples a day have been 
collected in our study. As the cortisol secretion is known to be influenced by factors which 
can hardly be controlled, these profiles were collected twice for each individual. As expected, 
cortisol levels were highest in the morning samples followed by a decline throughout the day.  
Further studies would be valuable to investigate the association between alexithymia and 
cortisol response as endocrine parameter. To conclude, the results from the current 
investigation suggest that pre-existing hypocortisolism might possible is associated with 
SFD. 
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Table 1: Demographic and clinical characteristics of patients with SFD and healthy 
controls (Standard deviations are presented in parentheses)  
Variable Patients with SFD 
n=32 
Healthy Controls (HC) 
N=25 
Age 44.2 (8.2) 37.4 (13.3) 
Gender (female/male) 23 / 9 19 / 6 
Higher education (%) 60% n.d. 
Somatization severity Index (SOMS) 21.4 (8.3) n.d. 
Global severity index (SCL-90-R) 64.2(13.6) n.d. 
Phobic anxiety (SCL-90-R) 58.9(11.5) n.d. 
HAM-D 13.2(3.9) n.d. 
BDI 16.5(9.2) n.d. 
TAS-26 Total Score 55.6(9.6) n.d. 
TAS factor 1: Difficulty identifying 
feelings 
60.6(8.8) n.d. 
TAS factor 2: Difficulty expressing 
feelings 
54.6(11.3) n.d. 
TAS factor 3: Difficulty externally 
orientated thinking 
45.38(9.0) n.d. 
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Table 2: Correlation between SCL-90-R-scale and Alexithymiascores (TAS) 
 
 
TAS factor 1: 
Difficulty Identifying 
feelings  
TAS factor 2: 
Difficulty describing 
feelings 
TAS factor 3: 
Externally orientated 
thinking 
TAS-26 Total 
Score 
Somatization Severity Index 
(SOMS) 
0.035 -0.094 -0.115 -0.102 
0.847 0.602 0.522 0.571 
SCL-90-R-scale     
(1) Somatization  0.343 * 0.054 -0.317 0.136 
0.050 0.769 0.077 0.456 
(2) Obsessive-Compulsive  0.542 * 0.396 * -0.191 0.464 * 
0.001 0.025 0.296 0.007 
(3) Interpersonal Sensitivity  0.748 * 0.388 * -0.321 0.525 * 
0.000 0.028 0.073 0.002 
(4) Depression  0.723 * 0.474 -0.260 0.554 * 
0.000 0.006 0.150 0.001 
(5) Anxiety  0,685 * 0.381 * -0.295 0.448 * 
0.000 0.031 0.101 0.010 
(6) Aggression  0,647 * 0.334 -0.268 0.431 * 
0.000 0.062 0.138 0.014 
(7) Phobic Anxiety 0,403 * 0.295 -0.320 0.264 
0.022 0.101 0.075 0.145 
(8) Paranoid Ideation 0,509 * 0.228 -0.368 * 0.317 
0.003 0.209 0.038 0.077 
(9) Psychoticism  0.721 0.272 -0.305 0.417 * 
0.000 0.132 0.090 0.018 
General Severity Index (GSI) 0.781 * 0.397 * -0.372 * 0.517 * 
0.000 0.024 0.036 0.002 
 
*. The Spearman Rank correlation is significant on the level of 0,05 (two-tail-probability) 
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Table 3: Mean serum levels (ng/ml) of cortisol for the patients with SFD and healthy 
controls (Standard deviations are presented in parentheses) 
 
 
*Significance determined using t-test with adjusted alpha for multiple comparisons 
 
 
Cortisol level 
(ng/ml) 
Patients with SFD 
(n=32) 
Healthy Controls 
(n=25) 
P-Value* 
Mean morning 
cortisol 
5.2 (3.2) 6.7 (3.9) p = 0.16 
AUC (G) 7.7 (3.4) 21.4 (10.3) p < 0.01 
AUC (I) -8.3 (7.7) -29.7 (24.8)  p < 0.01 
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Table 4. Relationship of alexithymia-scores, somatization, depression and GSI (Global severity 
index) to cortisol variables 
 AUC-G 
R2 = .465 (p<0.01) 
AUC-I 
R2 = .05 (p=0.22) 
MCS (Mean morning 
cortisol) 
R2 = .08 (p=0.12) 
Dependent variables 
 ßa t (p) ß t (p) ß t (p) 
Constant  2.16 (0.04)  -0.85 (0.4)  1.61 (0.12) 
Age 0.03 0.13 (.0.9) -0.17 -0.56 (0.58) 0.14 0.48 (0.63) 
HAM-D - 0.44 + -2.65 (0.01) -0.39 -1,17 (0.26) 0.05 0.16 (0.88) 
BDI 0.04 0.13 (0.9) 0.35 0,96 (0.35) -0.23 -0.67 (0.51) 
Somatization 
severity scale° 
(SOMS) 0.54 + 2.91 (0.01) -0.01 -0,02 (0.99) 0.36 1.32 (0.2) 
 GSI°° 
(SCL-90-R) 0.72 + 4.18 (0.01) -0.13 -0,28 (0.78) 0.51 1.21 (0.24) 
Somatization 
(SCL-90-R)  - 0.47 + -2.2 (0.04) 0.06 0.18 (0.86) -0.4 -1.17 (0.26) 
 TAS, “Total 
score” 1.03 1.9 (0.07) -0.65 -0.89 (0.39) 1.04 1.51 (0.15) 
TAS, “Difficulty 
identifying 
feelings” - 0.7 -1.82 (0.08) 0.56 1.07 (0.3) -0.79 -1.62 (0.12) 
TAS, “Difficulty 
describing 
feelings” - 0.45 -1.46 (0.16) 0.08 0.2 (0.84) -0.31 -0.8 (0.43) 
TAS, “Externally 
orientated 
thinking” - 0.56 -1.9 (0.07) 0.58 1.47 (0.16) -0.72 -1.95 (0.06) 
Predictor 
variables 
a Standardized regression coefficients (ß) are presented which indicate the relative magnitude of prediction 
for each independent variable. Coefficients printed in bold and marked with + were included in regression 
function. The other variables were excluded (SPSS backwards method). 
b df = 8 / 30 
° Number of symptoms; °° General Symptomatic Index SCL-90-R 
